Several pulmonary-related diseases could potentially benefit from treatments using the DryNeb technology, such as Lower Respiratory Track Infections, Cystic Fibrosis, Pulmonary Fibrosis, Lung Cancer, and Respiratory Syncytial Virus. Additionally, some non-pulmonary diseases might benefit too by using the lungs for delivery of new medicines.

These diseases impact millions of patients.   

Therapeutics using the DryNeb to treat these diseases could include both traditional, small-molecule therapeutics and newer technologies (e.g., biologics, vaccines).

With the DryNeb, the targeted delivery of medicine to the lungs can help minimize drug side effects and toxicities while still providing high concentrations of drug to the site of disease or infection.